SERES THERAPEUTICS INC (MCRB)

US81750R1023 - Common Stock

0.9155  -0.01 (-0.59%)

After market: 0.958 +0.04 (+4.64%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MCRB. MCRB was compared to 568 industry peers in the Biotechnology industry. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability. MCRB has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MCRB has reported negative net income.
In the past year MCRB has reported a negative cash flow from operations.
In the past 5 years MCRB always reported negative net income.
MCRB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of MCRB (-14.25%) is better than 83.54% of its industry peers.
Looking at the Return On Equity, with a value of -106.51%, MCRB is in line with its industry, outperforming 44.60% of the companies in the same industry.
Industry RankSector Rank
ROA -14.25%
ROE -106.51%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-40.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

MCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
MCRB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MCRB has more shares outstanding
MCRB has a worse debt/assets ratio than last year.

2.2 Solvency

MCRB has an Altman-Z score of -9.39. This is a bad value and indicates that MCRB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.39, MCRB is not doing good in the industry: 72.04% of the companies in the same industry are doing better.
There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.39
ROIC/WACCN/A
WACC14.17%

2.3 Liquidity

MCRB has a Current Ratio of 1.12. This is a normal value and indicates that MCRB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.12, MCRB is not doing good in the industry: 86.02% of the companies in the same industry are doing better.
MCRB has a Quick Ratio of 1.12. This is a normal value and indicates that MCRB is financially healthy and should not expect problems in meeting its short term obligations.
MCRB's Quick ratio of 1.12 is on the low side compared to the rest of the industry. MCRB is outperformed by 84.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MCRB have decreased by -6.25% in the last year.
The Revenue for MCRB has decreased by -99.95% in the past year. This is quite bad
The Revenue has been growing by 34.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.7%
Revenue 1Y (TTM)-99.95%
Revenue growth 3Y56.12%
Revenue growth 5Y34.88%
Sales Q2Q%-100%

3.2 Future

MCRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.10% yearly.
MCRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y18.78%
EPS Next 2Y17.13%
EPS Next 3Y14.86%
EPS Next 5Y43.1%
Revenue Next Year-100%
Revenue Next 2Y-65.85%
Revenue Next 3Y-46.49%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MCRB. In the last year negative earnings were reported.
Also next year MCRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

MCRB's earnings are expected to grow with 14.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.13%
EPS Next 3Y14.86%

More info and screens

0

5. Dividend

5.1 Amount

MCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERES THERAPEUTICS INC

NASDAQ:MCRB (12/20/2024, 8:23:46 PM)

After market: 0.958 +0.04 (+4.64%)

0.9155

-0.01 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners37.19%
Inst Owner Change-9.09%
Ins Owners0.9%
Ins Owner Change9.31%
Market Cap156.31M
Analysts75.38
Price Target3.95 (331.46%)
Short Float %11.75%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.27%
Min EPS beat(2)-51.81%
Max EPS beat(2)21.28%
EPS beat(4)3
Avg EPS beat(4)7.17%
Min EPS beat(4)-51.81%
Max EPS beat(4)36.89%
EPS beat(8)4
Avg EPS beat(8)0.85%
EPS beat(12)4
Avg EPS beat(12)-3.47%
EPS beat(16)6
Avg EPS beat(16)10.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.51%
PT rev (3m)11.64%
EPS NQ rev (1m)17.94%
EPS NQ rev (3m)17.94%
EPS NY rev (1m)23.61%
EPS NY rev (3m)26.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2442.38
P/FCF N/A
P/OCF N/A
P/B 6.54
P/tB 6.54
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.25%
ROE -106.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-40.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.33%
Cap/Sales 1820.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -9.39
F-Score2
WACC14.17%
ROIC/WACCN/A
Cap/Depr(3y)145.57%
Cap/Depr(5y)91.76%
Cap/Sales(3y)50.41%
Cap/Sales(5y)31.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.7%
EPS Next Y18.78%
EPS Next 2Y17.13%
EPS Next 3Y14.86%
EPS Next 5Y43.1%
Revenue 1Y (TTM)-99.95%
Revenue growth 3Y56.12%
Revenue growth 5Y34.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-65.85%
Revenue Next 3Y-46.49%
Revenue Next 5Y-14.87%
EBIT growth 1Y0.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.7%
EBIT Next 3Y15.34%
EBIT Next 5YN/A
FCF growth 1Y32.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31%
OCF growth 3YN/A
OCF growth 5YN/A